Doravirine vs Rilpivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Rilpivirine · Edurant

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00540449 · Phase 3 · completed

This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.

Next expected readout: December 2028 · NCT07637877 (registry estimate)

Reported efficacy

Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)

Result source: NCT00540449

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDoravirineRilpivirine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT042237780.6% vs 0%vs FTC/RPV/TDFwk 48 · n 316NCT02345252
3 other results
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 1% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305

HIV-1 RNA below 50 copies/mL (week 48)

Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
Rilpivirine
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791

HIV-1 RNA 50 copies/mL or more (week 48)

Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
Rilpivirine
0.6% vs 0%vs FTC/RPV/TDFwk 48 · n 316NCT02345252
3 other results
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 1% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226

CD4 count, change (week 48)

Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
Rilpivirine
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Doravirine: 8 of 8 rows · Rilpivirine: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDoravirine
Rows use multiple source trials
Rilpivirine
Rows use multiple source trials
CD4
percent change · % of baseline
No placebo or comparator arm
-0.4% (n=43) @ 48wka,b,c
NCT03332095 · Phase 1/2 · combination
6.4% (n=1) @ 48wkd,a,b,c
NCT04012931 · Phase 2 · registry result, not featured evidence
show 1 more dose
0.7% (n=25) @ 48wk
NCT04012931 · Phase 2 · registry result, not featured evidence
CD4+
absolute change · cells/uL
No placebo or comparator arm
42.5 cells/uL @ 96wke,b,c
NCT03332095 · Phase 1/2 · combination
72.63 cells/uL @ 96wkd,e,b,c
NCT01266902 · Phase 3 · registry result, not featured evidence
show 3 more doses
69.76 cells/uL @ 96wk
NCT01266902 · Phase 3 · registry result, not featured evidence
55.91 cells/uL @ 96wk
NCT01266902 · Phase 3 · registry result, not featured evidence
42.19 cells/uL @ 96wk
NCT01266902 · Phase 3 · registry result, not featured evidence
Hip BMD
percent change · % of baseline
Maintenance
0.6% (n=35) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mgd,f,g,c
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
-0.81% (n=40) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
1.279% (n=347) vs -0.134% (n=367) EFV/FTC/TDF @ 48wkf,g,c
NCT02345226 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
92.5% (n=40) @ 96wke,b,h
NCT03332095 · Phase 1/2 · combination
85% (n=252) @ 148wke,b,h
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
84% (n=261) @ 148wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
24.2%100 mgi
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
24.3%j
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
20%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
5.2%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
6.1%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
22.3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
25.2%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
12.7%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
15.7%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
8.1%
NCT01252940 · Phase 3 · registry result, not featured evidence
21%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
30.6%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
40%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
33.3%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
12.1%
NCT02165202 · Phase 2 · registry result, not featured evidence
4%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
7.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
1.6%100 mgi
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
3.5%j
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
5.3%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
2.4%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4.2%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01709084 · Phase 3 · registry result, not featured evidence
3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
2.5%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
0.6%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
1.1%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
0.9%
NCT01252940 · Phase 3 · registry result, not featured evidence
3%
NCT01309243 · Phase 3 · registry result, not featured evidence
—
NCT04012931 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—
NCT02165202 · Phase 2 · registry result, not featured evidence
—
NCT01286740 · Phase 2 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
—
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
11.7%100 mgi
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
11.6%j
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
9.4%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
—DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
3.2%DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
13.5%DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4%DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
5.8%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
14.6%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.3%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
4.4%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
7.6%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
11.4%FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
5.3%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
12.3%FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
4.8%Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
6.6%
NCT01252940 · Phase 3 · registry result, not featured evidence
9.1%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
16.7%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
4.4%
NCT02165202 · Phase 2 · registry result, not featured evidence
2%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
0%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
100 mgi
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
j
upper respiratory tract infection 15.3%
diarrhoea 14.7%
headache 14.5%
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 28 more results
headache 17.9%
nausea 16.8%
nasopharyngitis 14.7%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
arthralgia 0%
back pain 0%
bronchitis 0%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 20.6%
headache 14.7%
diarrhoea 13.9%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
headache 9.5%
diarrhoea 8.7%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
arthralgia 0%
asthenia 0%
back pain 0%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 18.4%
upper respiratory tract infection 14.2%
bronchitis 10.7%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 8%
upper respiratory tract infection 7.3%
arthralgia 6.5%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 29.6%
headache 17.8%
urinary tract infection 13.6%
NCT01709084 · Phase 3 · registry result, not featured evidence
pregnancy 1.9%
headache 1.1%
alanine aminotransferase increased 0.8%
NCT01266902 · Phase 3 · registry result, not featured evidence
facial wasting 1.7%
hepatitis c 1.7%
hypertension 1.7%
NCT01266902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
upper respiratory tract infection 14.9%
diarrhoea 10.8%
NCT02345252 · Phase 3 · registry result, not featured evidence
back pain 10.5%
conjunctivitis allergic 10.5%
cough 10.5%
NCT02345252 · Phase 3 · registry result, not featured evidence
cough 17.6%
nasopharyngitis 17.6%
pyrexia 17.6%
NCT02345252 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16.9%
nasopharyngitis 11.6%
cough 10.3%
NCT02345226 · Phase 3 · registry result, not featured evidence
cough 9.5%
diarrhoea 9.5%
eczema 9.5%
NCT02345226 · Phase 3 · registry result, not featured evidence
rhinitis 16%
nasopharyngitis 12%
bronchitis 8%
NCT02345226 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11%
diarrhoea 10.7%
headache 9.8%
NCT01252940 · Phase 3 · registry result, not featured evidence
diarrhoea 17.5%
nausea 16.5%
upper respiratory tract infection 14.5%
NCT01309243 · Phase 3 · registry result, not featured evidence
vomiting 15.4%
alanine aminotransferase increased 11.5%
abdominal pain 7.7%
NCT04012931 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
influenza 41.7%
cough 27.8%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 60%
toothache 40%
alanine aminotransferase increased 20%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
decreased appetite 22.2%
diarrhoea 22.2%
NCT00799864 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 100%
anaemia 50%
dermatitis atopic 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
12.5 mg
upper respiratory tract infection 100%
cough 50%
lower respiratory tract infection 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
injection site pain 75% (placebo 40.5%)
injection site pruritus 36.3% (placebo 11.9%)
injection site swelling 36.3% (placebo 7.1%)
NCT02165202 · Phase 2 · registry result, not featured evidence
diarrhoea 16.3%
upper respiratory tract infection 14.3%
insomnia 12.2%
NCT01286740 · Phase 2 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence
insomnia 23.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 1/2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 3 versus Phase 1/2.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gPopulation context differs: registered conditions differ.
  8. hAssessment timepoints differ: 148 weeks versus 96 weeks.
  9. iPopulation comparability has not been reviewed for 24 of these studies.
  10. jPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Doravirine

LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Total Cholesterol Change mg/dL -1.37 mg/dL @ 48wk100 mg
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02275780 · Phase 3 · combination
Triglyceride Change mg/dL -3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HIV-1 RNA Less Than 40 Copies 83.3% (n=383) vs 79.1% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · combination
show 3 more results
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
83.8% (n=364) vs 79.7% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Triglycerides -12.4% (n=333) vs 22.01% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
HDL-C 1.86% (n=333) vs 8.51% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3

+ 36 further endpoints in the CSV export.

Rilpivirine

Virologic Response Rate Lt50 Copies 82.9% (n=346) vs 82.8% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 287 Participants as posted
show 2 more results
76% (n=346) vs 78.8% (n=344) Efavirenz @ 96wk*
Responder
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 263 Participants as posted
95% (n=258) vs 96.3% (n=271) Efavirenz*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 245 Participants as posted
Virologic Response Rate Lt50 Copies 82.4% (n=346) vs 81.7% (n=344) Efavirenz @ 48wk
responder rate · % of participants
Virologic Response HIV RNA <50 copies/mL at Wk 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 285 Participants as posted
Virologic Response Rate Lt50 Copies 76.6% (n=346) vs 77.9% (n=344) Efavirenz @ 96wk
responder rate · % of participants
Virologic Response, <50 copies/ml
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 265 Participants as posted
Virologic Response Rate Lt400 Copies 85.8% (n=346) vs 85.2% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 297 Participants as posted
show 1 more result
78.9% (n=346) vs 80.8% (n=344) Efavirenz @ 96wk*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 273 Participants as posted
CD4+ 195.5 vs 181.6 Efavirenz cells/uL @ 48wk
absolute change · cells/uL
Absolute cell count, Week 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
188.6 vs 170.7 Efavirenz cells/uL @ 48wk
Absolute cell count, Week 48
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
CD4+ 220.7 vs 226.7 Efavirenz cells/uL @ 96wk
absolute change · cells/uL
Absolute cell count, Week 96
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
234.5 vs 212 Efavirenz cells/uL @ 96wk
Absolute cell count, Week 96
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
Virological Response 50 Copies TLOVR 85.6% (n=340) vs 81.7% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 291 Participants as posted
show 1 more result
79.1% (n=340) vs 76.3% (n=338) Efavirenz @ 96wk*
Responder
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 269 Participants as posted
Virological Response 50 Copies Snapshot 82.6% (n=340) vs 78.4% (n=338) Efavirenz @ 48wk
event count · % of participants
Virologic Response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 281 Participants as posted
show 1 more result
76.2% (n=340) vs 75.1% (n=338) Efavirenz @ 96wk*
Virologic response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 259 Participants as posted
Virological Response 400 Copies TLOVR 88.2% (n=340) vs 84.6% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 300 Participants as posted
show 1 more result
83.2% (n=340) vs 79.9% (n=338) Efavirenz @ 96wk*
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 283 Participants as posted
HIVTSQc 0 vs 0 Current Antiretroviral Regimen (CAR) score @ 4wk
absolute change · score
Total score, Week 4
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 1 vs 0 Current Antiretroviral Regimen (CAR) score @ 24wk
absolute change · score
Total score, Week 24
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 0.5 vs 0 Current Antiretroviral Regimen (CAR) score @ 48wk
absolute change · score
Total score, Week 48
NCT02429791 · Phase 3 · registry result, not featured evidence · combination

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Rilpivirine's landscape